Balaxi Pharmaceuticals Reports Strong Q2 FY27 Earnings Growth
Balaxi Pharmaceuticals Ltd · Press Release · 13 Nov 2026, 2:20 am
Balaxi Pharmaceuticals Reports Strong Q2 FY27 Earnings Growth Balaxi Pharmaceuticals reported strong consolidated Q2 FY27 results on 12th Nov'26, with revenue from operations growing 44.85% YoY to ₹8,137.23 lakh. EBITDA surged 338.19% YoY to ₹512.07 lakh as EBITDA margin expanded 421 bps to 6.29%. Net profit rose 450.29% YoY to ₹115.01 lakh, with diluted EPS increasing to ₹0.21. For H1 FY27, revenue reached ₹16,205.40 lakh (up 27.68% YoY) and PAT stood at ₹244.76 lakh (up 390.30% YoY). The company added 31 new registrations and operationalized its Jadcherla formulation facility.
Original exchange filing (PDF)
More announcements from Balaxi Pharmaceuticals Ltd
- BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Investor Presentation · 16 Nov 2026
- Balaxi Pharmaceuticals Limited has informed the Exchange regarding Progress of the Company's Pharmaceutical Formulation Plant at Jadcherla, Hyderabad. · 12 Nov 2026
- BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about change in Management · 12 Nov 2026
- BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding Outcome of Board Meeting held on November 12, 2026. · 12 Nov 2026
- BALAXI PHARMACEUTICALS LIMITED has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 12 Nov 2026
- BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding ''RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the period ended October 2026". · 12 Nov 2026
- BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 12-Nov-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Other business. · 12 Nov 2026
- To consider and approve the Unaudited Standalone and Consolidated financial results of the Company for the second quarter and half year ended 30th September, 2026 of the Financial Year 2026-27, and other business matters. · 12 Nov 2026
